Tag:
Rigel Pharmaceuticals
Latest Headlines
Latest Headlines
AstraZeneca tosses another PhIII failure onto the scrap heap
AstraZeneca just can't catch a break. After looking over lackluster late-stage results for its rheumatoid arthritis drug fostamatinib, the pharma giant has opted to scrap its development efforts and turn the whole program back over to Rigel, the biotech partner which had licensed it to them in the first place
AstraZeneca reports hit-and-miss PhIII for arthritis pill
The London drug giant missed one out of two main goals for the study of fostamatinib, leaving the prospects of the candidate open to skepticism after it fell short of matching the efficacy of AbbVie's Humira in an earlier mid-stage trial.
AstraZeneca and Rigel strike asthma deal worth up to $100M
The deal hinges on Rigel's candidate known as R256, an inhalable JAK inhibitor under evaluation for treating tough cases of asthma.
Germany's 4SC misses mark in key RA drug trial, CEO keeps faith
Falling short of its primary goal in a mid-stage study for an oral drug in rheumatoid arthritis patients, German biotech 4SC ( $VSC ) is keeping its chin up in pursuit of a partner to take the
Rigel raises $130M for PhII trial of asthma drug
Pfizer's decision to cut all allergy and respiratory drug development work came as good news for Rigel Pharmaceuticals, even though it meant the end of the two developers' pact for allergic asthma
Pfizer returns allergic asthma drug to Rigel
Pfizer's decision to end its allergy and respiratory R&D work has prompted the company to return rights to the R343 program for allergic asthma to Rigel Pharmaceuticals . The drug has shown
AZ pushes pedal to metal on PhIII oral RA blitzkrieg
Just six months after AstraZeneca paid $100 million upfront to grab the licensing rights to Rigel's promising oral rheumatoid arthritis therapy , the pharma giant is ramping up a slate of late-stage
AZ/Rigel RA drug hits PhIIb paydirt
AstraZeneca's $100 million upfront wager on Rigel's experimental rheumatoid arthritis therapy R788 has paid off with a promising set of mid-stage data just as the partners prepare for their Phase III
Was Rigel's $1.2B RA deal over-hyped?
When Rigel Pharmaceuticals rolled out its new partnership with AstraZeneca for R788 (fostamatinib) last week, it had all the ingredients for a big day on Wall Street: A big pharma partner name, a
Rigel says it's nearing psoriasis pact
Fresh on the heels of a newly-announced $1.24 billion pact on a rheumatoid arthritis drug, Rigel Pharmaceuticals says it's nearing another deal on its psoriasis program. "We are continuing to work on
